This Morning's Technical Outlook on Medical Research Stocks -- Bruker, Charles River Labs, DexCom, and Exact Sciences

Thursday, April 12, 2018 Research News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, April 12, 2018 /PRNewswire/ strives to bring the best free research to the investment community. 

Today we are offering reports on BRKR, CRL, DXCM, and EXAS which can be accessed for free by signing up to Research reports have been issued by on Bruker Corp. (NASDAQ: BRKR), Charles River
Laboratories International Inc. (NYSE: CRL), DexCom Inc. (NASDAQ: DXCM), and Exact Sciences Corp. (NASDAQ: EXAS). Medical Laboratories and Research companies focus on performing various tests on patients that give them information on patients' health. These firms, as a whole, tend to offer higher dividend yields than the wider Healthcare sector. All you have to do is sign up today for this free limited time offer by clicking the link below.


Billerica, Massachusetts headquartered Bruker Corp.'s shares declined slightly by 0.94%, closing Wednesday's trading session at $29.56. The stock recorded a trading volume of 601,598 shares, which was above its three months average volume of 578,030 shares. The Company's shares have advanced 31.73% over the past year. The stock is trading 5.06% below its 50-day moving average. Additionally, shares of Bruker, which develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions worldwide, have a Relative Strength Index (RSI) of 46.93. 

On April 10th, 2018 at Analytica 2018, Bruker announced the launch of the new INVENIO™ Fourier Transform Infrared (FT-IR) research spectrometer. The INVENIO is the successor to the renowned VERTEX 70 FT-IR for advanced R&D applications. Get the full research report on BRKR for free by clicking below at:

Charles River Labs International

Wilmington, Massachusetts headquartered On Wednesday, shares in Charles River Laboratories International Inc. recorded a trading volume of 143,256 shares. The stock declined slightly by 0.76%, ending the day at $105.29. The Company's shares have advanced 20.86% over the past year. The stock is trading below its 200-day moving average by 0.85%. Furthermore, shares of the Company, which provides drug discovery, non-clinical development, and safety testing services worldwide, have an RSI of 48.07. 

On April 03rd, 2018, Charles River Labs announced that it has closed its previously announced offering of $500 million in aggregate principal amount of its 5.5% senior notes due 2026 in an unregistered offering. CRL's complimentary research coverage is a few simple steps away at:


San Diego, California headquartered DexCom Inc.'s stock finished the day 0.45% lower at $70.96. A total volume of 1.53 million shares was traded, which was above their three months average volume of 1.14 million shares. The Company's shares have advanced 10.72% in the last month and 29.96% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 14.54% and 15.43%, respectively. Additionally, shares of DexCom, which focuses on the design, development, and commercialization of continuous glucose monitoring systems in the US and internationally, have an RSI of 63.32. 

On April 04th, 2018, research firm Guggenheim initiated a 'Neutral' rating on the Company's stock.

On April 04th, 2018, DexCom announced plans to release its Q1 2018 financial results after market close on May 02nd, 2018. Management will hold a conference call at 4:30 p.m. ET that same day to review the Company's performance. The conference call will be concurrently webcast and will be available on the Company's website. Register for your free research report on DXCM at:

Exact Sciences

Shares in Madison, Wisconsin headquartered Exact Sciences Corp. ended yesterday's session 2.92% higher at $42.36. The stock recorded a trading volume of 1.76 million shares. The Company's shares have surged 85.63% over the past year. The stock is trading 8.72% below its 50-day moving average. Moreover, shares of Exact Sciences, which focuses on developing products for the early detection and prevention of various cancers in the US, have an RSI of 45.97. 

On April 03rd, 2018, research firm BTIG Research upgraded the Company's stock rating from 'Neutral' to 'Buy'.

On April 09th, 2018, Exact Sciences announced plans to release its Q1 2018 financial results after the close of the US financial markets on April 26th, 2018. Following the release, management will host a webcast and conference call at 5:00 p.m. EDT to discuss the Company's results and business progress. The live webcast of the call can be accessed on the Company's website. Wall St. Equities' downloadable research report on EXAS available at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:


Phone number: +21-32-044-483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Cision View original content:

SOURCE Wall St. Equities

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store